RED-Institut GmbH

Running trials

• Not yet recruiting

  A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes

  NCT07881432· Phase 3· Source

• Recruiting

  A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes

  NCT07881458· Phase 3· Source

• Recruiting

  A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

  NCT07369011· Phase 3· Source

• Active, not recruiting

  Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

  NCT07225686· Phase 3· Source

• Active, not recruiting

  Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

  NCT07226765· Phase 3· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Source

• Active, not recruiting

  A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

  NCT06972472· Phase 3· Source

• Active, not recruiting

  A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

  NCT06993792· Phase 3· Source

• Active, not recruiting

  A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

  NCT06948435· Phase 3· Source

• Active, not recruiting

  A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

  NCT06952530· Phase 3· Source

• Active, not recruiting

  A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

  NCT06948422· Phase 3· Source

• Active, not recruiting

  Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

  NCT06858878· Phase 3· Source

• Active, not recruiting

  Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

  NCT06858839· Phase 3· Source

• Active, not recruiting

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity3 recruiting
• Type 2 diabetes2 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

  NCT06649045· Phase 3· Source

• Completed

  A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

  NCT05872620· Phase 3· Source